EUCTR2005-005778-63-IT进行中（未招募）不适用
Phase II study of Glivec (imatinib mesylate) in patients with advanced neuroblastoma - ND
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •-Age between 1 and 21 years at the time of treatment -diagnosis of neuroblastoma according to INSS criteria -Disease status: patients with advanced disease (stage 4) achieving< CR-VGPR at the completion of first or second line treatment or patients with metastatic relapse-progression of the disease after first-line treatment
- •Are the trial subjects under 18? yes
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) no
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •-Patients with severe organ dysfunction -known HIV infection -active HBV-HCV infection
研究者
相似试验
已完成
2 期
Phase2 Study of Glivec (imatinib mesylate, formerly known as STI571) in Patients with Relapsed or Refractory Sarcomas with c-kit or PDGFR ExpressioJPRN-jRCT1091220003Office of Imatinib phase 2 study40
已完成
2 期
Phase2 Study of Glivec (imatinib mesylate, formerly known as STI571) in Patients with Relapsed or Refractory Sarcomas with c-kit or PDGFR ExpressioSarcoma with c-kit or PDGFR expression by immunohistochemistryJPRN-C000000073Office of Imatinib phase2 study40
已完成
2 期
Glivec plus chemotherapy in blast-phase CML and Ph+ ABlast-Phase Chronic Myeloid LeukemiaPhiladelphia Chromosome-Positive Acute Lymphoblastic LeukemiaCancer - Leukaemia - Acute leukaemiaCancer - Leukaemia - Chronic leukaemiaACTRN12605000072617Australasian Leukaemia and Lymphoma Group41
进行中（未招募）
1 期
Phase 2 study of Glivec (Imatinib) in locally advanced and/or metastatic soft tissue sarcomas expressing the t(17;22)(q22;q13) translocation resulting in a COL1A1/PDGF rearrangement i.e. DermatoFibroSarcoma Protuberans (DFSP) and Giant Cell Fibroblastoma (GCF)EUCTR2004-002538-20-GBEuropean Organisation for Research and Treatment of Cancer44
已完成
2 期
Imatinib Mesylate in Treating Patients With Stage IV Colorectal CancerRecurrent Colon CancerRecurrent Rectal CancerStage IV Colon CancerStage IV Rectal CancerNCT00041340National Cancer Institute (NCI)37